FGFR Inhibitor Shows Promise in Advanced Urothelial Carcinoma
A phase II study found that the FGFR inhibitor erdafitinib yields a good response rate and was well tolerated in patients with urothelial carcinoma and FGFR alterations.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Source Type: news